Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scientists Develop New Treatments for Alzheimer’s Disease

27.10.2006
Scientists at the University of Liverpool have created a new chemical compound that could be developed into a drug treatment for Alzheimer’s disease.

The research team has used a family of long chain sugars called Heparan Sulphates (HS), found on nearly every cell of the body, to produce a new compound that can prevent the formation of clumps of small proteins that form in the brain. These clumps or ‘plaques’ disrupt the normal function of cells leading to progressive memory loss which is characteristic of Alzheimer’s disease.

The clumps are formed from a small protein fragment called Amyloid-beta (A-beta) peptide released from its ‘parent’ protein - amyloid precursor protein (APP). This process requires the action of an enzyme called beta-secetase (BACE), which is critical in clipping up the APP to form the smaller A-beta fragments.

Professor Jerry Turnbull and Dr Ed Yates, from the University’s School of Biological Sciences, have discovered that the HS sugars may play a key role in limiting the development of Alzheimer’s disease. The sugars stick to the BACE enzyme and reduce its ability to ‘clip’ the A-beta peptide, thus controlling the amount of A-beta peptide available to form damaging plaques in brain tissue.

... more about:
»A-beta »Alzheimer »Fragment »Peptide »compound »enzyme

Professor Turnbull said: “We have developed a new class of compounds called ‘engineered heparins’ that could possibly be developed into drugs to stop A-beta peptides in the brain from forming and for the first time treat the underlying cause of Alzheimer’s. The compound, based on the blood thinning drug, heparin, has modified chemical structures designed to optimise their desired activities and reduce potential side effects.

“The compounds work by blocking the beta-secretase enzyme, responsible for snipping proteins into smaller fragments. Despite its central importance to the disease, there are currently no drug treatments which target this enzyme because it has proved difficult to find inhibitors using traditional drug discovery approaches. The new compounds, based on the body’s natural substances, may provide a novel route to effective treatments for this debilitating disease.”

A spin-out company, IntelliHep Ltd, has also been founded to explore the commercial opportunities of developing engineering heparans as new drugs against Alzheimer’s and other important medical conditions.

The research, funded by the Medical Research Council and the Biotechnology and Biological Sciences Research Council, is published in the Journal of Medicinal Chemistry.

Samantha Martin | alfa
Further information:
http://www.liv.ac.uk/newsroom

Further reports about: A-beta Alzheimer Fragment Peptide compound enzyme

More articles from Life Sciences:

nachricht The balancing act: An enzyme that links endocytosis to membrane recycling
07.12.2016 | National Centre for Biological Sciences

nachricht Transforming plant cells from generalists to specialists
07.12.2016 | Duke University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>